Karam Mounzer is an Infectious Disease physician affiliated with The Wistar Institute. OpenAlex indexes 184 publications with 6,260 citations (h-index 40); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1233 Locust St Fl 4
Philadelphia, PA 191075459
Telephone
215-790-1788Registry record last updated 17 Mar 2018.
Clinical trials
- Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
Sponsor: The Wistar Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202581 payments$58,914openpaymentsdata.cms.gov ↗
- ViiV Healthcare CompanyProgram year202563 payments$48,781openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
26.6%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor7.5%Tivicay57%Dovato25%Isentress15%Juluca3%Part D<11 patientsProtease Inhibitor5.8%Prezcobix31%Darunavir29%Symtuza23%Prezista9%Ritonavir8%Part D<11 patients+ 8 more classes in this area
Cardiovascular
26.4%Statin8.1%Atorvastatin Calcium50%Rosuvastatin Calcium39%Pravastatin Sodium10%Part D<11 patientsBeta blocker4%Metoprolol Succinate42%Carvedilol26%Propranolol Hcl11%Metoprolol Tartrate10%Atenolol6%Propranolol Hcl Er5%Part D<11 patients+ 16 more classes in this area
Nervous system
16.2%SSRI4.3%Trazodone Hcl38%Escitalopram Oxalate32%Sertraline Hcl21%Fluoxetine Hcl9%Part D<11 patientsGabapentinoids4.1%Gabapentin75%Pregabalin25%Part D<11 patients+ 14 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
New England Journal of Medicine
2024 - The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
Journal of Clinical Investigation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”